Answers are grounded in this paper and cite their sources.
Allogeneic GM-CSF-secreting tumor vaccines are safe in patients with pancreatic adenocarcinoma. This vaccine approach seems to induce dose-dependent systemic antitumor immunity as measured by increased postvaccination DTH responses against autologous tumors. Further clinical evaluation of this approach in patients with pancreatic cancer is warranted.
No takes yet. Share an insight, caveat, or question.
Jaffee et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: